Questions about where asset managers’ and financial advisors’ responsibilities to clients lie are being clarified in regulatory and court decisions now on the horizon — and the answers appear to be moving in the direction of fiduciary obligation.
On Friday, a federal trial court in Connecticut ruled against the insurance company ING concerning its status as a fiduciary in defined contribution plan administration.
Healthcare Strategies, sponsor of a retirement plan that ING administers, claims that ING made fund choices for its guaranteed investment contract investment option based on the revenue-sharing benefits the company receives rather than choosing the most optimal choice for plan participants.
The Healthcare Strategies case received class-action certification, meaning that ING’s conduct in all plans it administers is at stake. The multinational insurance company sought to summarily dismiss the claim on the basis that it is legally entitled to act as alleged.
Top Heal Care Stocks To Invest In 2015: Korian SA (KORI)
Korian SA is a France-based company that operates healthcare facilities and medical establishments. The Company's holdings include residential centers for the elderly (EHPAD), offering permanent social care and medical support; follow-up care and rehabilitation centers, including general and specialized centers. Korian SA's establishments are located in France, Italy and Germany via its subsidiaries, Segesta S.p.A., Phonix GmBH, Reacti Malt SAS, Sas La Normandie, Sa La Bastide de la tourne, Sas Mapadex La Roseraie, among others. In March 8, 2013, it finalized the acquisition of Curanum AG by Korian SA's Korian Deutschland AG. In February 2014, it announced the acquisition of a clinic in Florence and the sale of the psychiatry division in France comprising seven clinics and two nursing homes. Advisors' Opinion:- [By Corinne Gretler]
Korian (KORI) declined 3.8 percent to 24.35 euros. The merger with Medica will create the largest French operator of nursing homes. Medica holders will receive Korian stock valued at about 23.01 euros a share, the companies said in a statement today. That�� 15 percent above Medica�� closing price on Nov. 15. Medica shares added 2.4 percent to 20.50 euros.
Top 10 Sliver Stocks To Invest In 2014: Dynavax Technologies Corporation(DVAX)
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company's lead product candidate includes HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than current licensed vaccines. It also develops Universal Flu vaccine, a Phase 1b clinical trial vaccine for influenza prevention; SD-101, a Phase Ib clinical trial hepatitis C therapy; DV-601, a Phase Ib clinical trial hepatitis B therapy; AZD1419, a preclinical asthma therapy; and DV1179, a Phase 1 trial autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline plc to discover, develop, and commercialize DV1179 and other endosomal toll-like receptor inhibitors for diseases, such as lupus, psoriasis, and rheumatoid arthritis; and develop a TLR8 inhibitor for the treatment of multiple autoimmune and i nflammatory diseases, as well as has research and license agreement with AstraZeneca to discover and develop TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was founded in 1996 and is based in Berkeley, California.
Advisors' Opinion:- [By Keith Speights]
Dynavax (NASDAQ: DVAX ) is a good case in point. The company's Heplisav hepatitis B vaccine looked good in clinical trials when compared to the leading vaccine on the market. Dynavax thought that the safety profile for Heplisav also compared favorably. The Food and Drug Administration even told the company that it could expand its Biologic License Application, or BLA, to include a wider age range of adults than originally planned.
- [By Roberto Pedone]
Another under-$10 bio therapeutic player that's starting to trend within range of triggering a major breakout trade is Dynavax Technologies (DVAX), which discovers and develops novel products to prevent and treat infectious and inflammatory diseases. This stock has been hit hard by the sellers so far in 2013, with shares off sharply by 55%.
If you take a look at the chart for Dynavax Technologies, you'll notice that this stock has been trending inside of a big range for the last three months and change, with shares moving between $1.10 on the downside and $1.46 on the upside. This large consolidation pattern for DVAX could mean that this stock is under accumulation by the bulls, since the bears have been unable to push the stock out of this range and take it to new lows. Shares of DVAX are now starting to spike back above its 50-day moving average of $1.25 a share with decent upside volume. Volume so far on Thursday has already registered 1.6 million shares versus its three-month average action or 1.81 million shares. This move is starting to push DVAX within range of triggering a major breakout trade.
Market players should now look for long-biased trades in DVAX if it manages to break out above some key overhead resistance levels at $1.29 to $1.32 a share, and then once it takes out more resistance at $1.46 to $1.50 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 1.81 million shares. If that breakout hits soon, then DVAX will set up to re-test or possibly take out its next major overhead resistance level at $1.70 a share. Any high-volume move above $1.70 a share will then give DVAX a chance to re-fill some of its previous gap down zone from June that started at $2.60 a share.
Traders can look to buy DVAX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.10 a sha
- [By Holly LaFon]
Steven Cohen, George Soros and John Paulson are three of the most formidable investors alive today. All three of them added to one of their major holdings so far in 2012. Steven Cohen of SAC Capital Advisors added Dynavax Tech Cp (DVAX), George Soros of Soros Fund Management LLC added Acacia Research (ACTG) and John Paulson of Paulson & Co. added Novagold Resources (NG).
Top 10 Sliver Stocks To Invest In 2014: Rossi Residencial SA (RSID3)
Rossi Residencial SA is a Brazil-based company involved in the real estate sector. The Company is principally engaged in the development, construction and sale of residential and commercial real estate properties. In addition, it is involved in the subdivision of land and provision of civil engineering services. As of December 31, 2011, the Company had four subsidiaries, including Astir Assessoria Tecnica Imobiliaria e Participacoes Ltda, RCI Consultoria de Imoveis Ltda, Rossi Consultoria de Imoveis Ltda and Rossi Industria de Artefatos de Concreto Ltda, as well as a number of joint ventures, such as Argentea Empreendimentos SA, Damacena Empreendimentos SA, Minulo Empreendimentos SA and Nicandra Empreendimentos SA, among others. Advisors' Opinion:- [By Ney Hayashi]
MMX Mineracao & Metalicos SA rose to a one-week high after saying it is seeking partners to expand a mining project. Rossi Residencial SA (RSID3) led gains among homebuilders as traders reduced bets on higher borrowing costs. EDP-Energias do Brasil SA advanced after selling a stake in some of its power plants in Brazil to China Three Gorges Corp. Car-rental company Localiza Rent a Car SA climbed after Fitch Ratings increased its credit rating.
- [By Ney Hayashi]
Rossi Residencial SA (RSID3) climbed 2.1 percent today to 2.98 reais, leading homebuilders higher, as traders pared bets for higher borrowing costs in Brazil following the inflation report. The BM&FBovespa Real Estate Index added 0.5 percent.
Top 10 Sliver Stocks To Invest In 2014: Otter Tail Corporation(OTTR)
Otter Tail Corporation engages in electric and nonelectric operations in the United States and internationally. It operates in six segments: Electric, Plastics, Manufacturing, Health Services, Food Ingredient Processing, and Other Business Operations. The Electric segment includes the production, transmission, distribution, and sale of electric energy through coal, wind, hydro, natural gas, and oil in Minnesota, North Dakota, and South Dakota. As of December 31, 2009, it provided electricity to approximately 130,900 customers, including residential, industrial, commercial, and other customers. This segment also operates as a wholesale participant in the Midwest Independent Transmission System Operator markets. The Plastics segment involves in producing polyvinyl chloride (PVC) pipes. The Manufacturing segment engages in the production of wind towers; contract machining; metal parts stamping and fabrication; production of waterfront equipment; and material and handling tray s, and horticultural containers. The Health Services segment sells diagnostic medical equipment, patient monitoring equipment, and related supplies and accessories. This segment also provides equipment maintenance service and diagnostic imaging services; and involves in the rental of diagnostic medical imaging equipment to various medical institutions. The Food Ingredient Processing segment produces dehydrated potato products. The Other Business Operations segment engages in residential, commercial, and industrial electric contracting; fiber optic and electric distribution systems; water, wastewater, and HVAC systems construction; and transportation and energy services businesses. The company was formerly known as Otter Tail Holding Company and changed its name to Otter Tail Corporation in 2001. Otter Tail Corporation was founded in 1907 and is based in Fergus Falls, Minnesota.
Advisors' Opinion:- [By Dividend]
Otter Tail (OTTR) has a market capitalization of $1.13 billion. The company employs 2,286 people, generates revenue of $859.24 million and has a net income of $38.97 million. Otter Tail�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $142.22 million. The EBITDA margin is 16.55 percent (the operating margin is 8.02 percent and the net profit margin 4.54 percent).
- [By Richard Stavros]
In examining the top two stock sellers and top two stock buyers listed above, we illustrate how these companies are managing their efforts to return cash to shareholders (See Chart C). The chart clearly shows that those firms that were making stock buybacks had better shareholder yields than those that were making stock issuances, namely Otter Tail Corp (NYSE: OTTR) and The AES Corp (NYSE: AES).
Top 10 Sliver Stocks To Invest In 2014: Alon USA Partners LP (ALDW)
Alon USA Partners, LP (Alon USA), incorporated on August 17, 2012, owns and operates refining and petroleum products marketing business. Its integrated downstream business operates primarily in the South Central and Southwestern regions of the United States. It owns and operates a crude oil refinery in Big Spring, Texas with total throughput capacity of approximately 70,000 barrels per day (bpd). The crude oil pipelines the Company utilizes consist of the Amdel, White Oil, Mesa Interconnect, Centurion and Centurion Interconnect. Its Big Spring refinery produces ultra-low sulfur gasoline, ultra-low sulfur diesel, jet fuel, petrochemicals, petrochemical feedstocks, asphalt and other petroleum products.
During the year ended December 31, 2011 and the six months ended June 30, 2012, sour crude, such as West Texas Sour (WTS), represented approximately 80.4% and 80.4% of its throughput, respectively, and sweet crude, such as West Texas Intermediate (WTI), represented approximately 15.8% and 17.1% of its throughput, respectively. For the year ended December 31, 2011 and the six months ended June 30, 2012, the Company produced approximately 49.1% and 49.2% gasoline, 32.3% and 32.5% diesel/jet fuel, 7.1% and 6.4% asphalt, 6.0% and 6.0% petrochemicals and 5.5% and 5.9% other refined products, in each case, respectively. The Company distributes fuel products through a product pipeline and terminal network of seven pipelines totaling approximately 840 miles and six terminals that it owns or access.
The Company competes with Chevron, ExxonMobil and Shell.
Advisors' Opinion:- [By Robert Rapier] In last week’s issue I discussed the basics of the refining sector. Today I will provide an overview of four MLPs that hold refining assets.
To review, the refining sector was very profitable in 2012 thanks to unusually high crack spreads, which for many US refiners are approximated by the price differential between Brent and West Texas Intermediate (WTI) crude oils. For a more thorough explanation of this phenomenon, please refer to last week’s issue.
After years of trading at a $1 to $3 per barrel discount to WTI, Brent began fetching a premium a few years ago as a glut of crude developed in the mid-continent area of the US. In 2011 the Brent-WTI price differential increased to more than $25/bbl, and it remained historically high in 2012.
But pipeline capacity started to catch up this year, and the share prices of refiners retreated as the glut began to dissipate and the Brent-WTI differential shrank. In Q3 2012, the Brent-WTI differential averaged $17.43/bbl, but by Q3 of this year, the differential had fallen to $4.43/bbl. This promises bad news for refiners about to report Q3 earnings.
Many analysts downgraded the refining sector in Q3, but as the differential fell below $5/bbl it was hard to imagine that the news could get much worse. With poor Q3 results largely priced in, the differential subsequently rose back above $10/bbl, signaling better refining margins moving into Q4.
Refiners began to post earnings this past week, and as expected they were weak. Valero (NYSE: VLO) reported slightly higher revenues year-over-year, but net earnings fell more than 50 percent from a year ago. Nevertheless, they beat the extremely pessimistic expectations of analysts, and Valero shares rose on the news.
Phillips 66’s (NYSE: PSX) refining unit actually posted a loss, but its chemical business turned in a solid quarter which more than compensated for the disappointing refining results.
The rest of the refine - [By Robert Rapier]
I warned last week that refiners would report relatively poor earnings for Q3, and refinery MLPs could take a hit, presenting a buying opportunity. On Nov. 6 Alon USA Partners (NYSE: ALDW) reported a loss for the third quarter of $16.1 million, or ($0.26) per unit, compared with net income of $120.4 million for the same period last year. Paul Eisman, CEO and president, cited the deteriorating margins that I discussed in last week’s issue: “Our third quarter results were impacted by a volatile and deteriorating margin environment resulting primarily from decreasing discounts for West Texas crude oil.”
- [By Tom Dorsey]
Over a several day period, I submitted questions and Mr. Eisman, President, Chief Executive Officer and Director of Alon USA Energy Inc. (ALJ) and the parent company of Alon USA Partners LP Inc. (ALDW) responded. He provided some key insights to some challenges the company faces, where the company is going, and the opportunities available in the future. This insight should provide investors with additional information to understand the value of the company and the opportunity as an investor in the company.
- [By Ben Levisohn]
How bad has this week been? Marathon Petroleum has fallen 4.3% through yesterday’s close, while HollyFrontier has dropped 2.5%, Valero Energy (VLO) has declined 3.5% and Alon USA Partners (ALDW) has slipped 5.7%. Western Refining (WNR) has weathered the selling and has ticked down just 0.3%.
Top 10 Sliver Stocks To Invest In 2014: Navios Maritime Partners LP (NMM)
Navios Maritime Partners L.P. (Navios Partners) is an international owner and operator of dry cargo vessels formed by Navios Holdings. Navios GP L.L.C. (the General Partner), a wholly owned subsidiary of Navios Maritime Holdings Inc. (Navios Holdings) acts as the general partner of Navios Partners and received a 2% general partner interest in Navios Partners. Navios Partners is engaged in the seaborne transportation services of a range of drybulk commodities, including iron ore, coal, grain and fertilizer, chartering its vessels under medium to long-term charters. On May 19, 2011, Navios Partners acquired from Navios Holdings the Navios Orbiter, a 76,602 deadweight Panamax vessel. On May 19, 2011, Navios Partners acquired from Navios Holdings the Navios Luz. In June 2012, the Company purchased the Navios Buena Ventura, a 2010 South-Korean-built Capesize vessel of 179,259 dwt from Navios Maritime Holdings Inc.
The Company is an international owner and operator of drybulk carriers formed by Navios Maritime Holdings Inc., a vertically integrated seaborne shipping company. Its vessels are chartered-out under medium to long-term time charters with an average remaining term of approximately four years to a group of counterparties, consisting of Cosco Bulk Carrier Co. Ltd., Mitsui O.S.K. Lines Ltd., Samsun Logix, STX Panocean, Sanko Steamship Co. Ltd., Daiichi Chuo Kisen Kaisha, Augustea Imprese Maritime, Rio Tinto, Constellation Energy Group and Mansel.
As of December 31, 2011, the Company�� fleet consisted of 11 Panamax vessels, six Capesize vessels and one Ultra-Handymax vessel. Its fleet of dry cargo vessels has an average age of approximately 5.6 years. Panamax vessels are flexible vessels capable of carrying a range of drybulk commodities, including iron ore, coal, grain and fertilizer. All of its vessels operate under medium to long-term time charters of three or more years at inception with counterparties. It also operates vessels in the spot market until the vessels have! been fixed under appropriate medium to long-term charters.
The Company competes with China Ocean Shipping, China Shipping Group, Mitsui O.S.K. Lines, Kawasaki Kisen, Nippon Yusen Kaisha, Cargill, Pacific Basin Shipping, Bocimar, Zodiac Maritime, Louis Dreyfus/Cetragpa, Cobelfret and Torvald Klaveness.
Advisors' Opinion:- [By Robert Rapier]
The index includes everything from behemoths like Enterprise Product Partners (NYSE: EPD) and Kinder Morgan Energy Partners (NYSE: KMP) down to a pair with market capitalizations under $1 billion in Martin Midstream Partners (NASDAQ: MMLP) and Navios Maritime Partners (NYSE: NMM). The total market cap of the index is $328 billion, and its one-, three- and five-year total returns are 20 percent, 48 percent and 194 percent. The index yield is 6 percent.
- [By Robert Rapier]
Some of our portfolio picks that are suitable for IRA accounts include Kinder Morgan (KMI), Williams (WMB), Targa Resources (TRGP) and Navios Maritime Partners (NMM).
Top 10 Sliver Stocks To Invest In 2014: Cleveland BioLabs Inc.(CBLI)
Cleveland BioLabs, Inc., a biotechnology company, engages in the discovery, development, and commercialization of products for cancer treatment, and protection of normal tissues from radiation and other acute stresses. Its products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and the intestines; Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation; and Curaxins, which are small molecules intended to destroy tumor cells by simultan eously targeting two regulators of apoptosis. The company has a strategic research partnership with Roswell Park Cancer Institute to develop its anticancer and radioprotectant drug candidates; a strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds; and a strategic alliance with The Cleveland Clinic Foundation (CCF). It also has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences; the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.; and CCF to evaluate its radioprotective drug candidates and their effects on intracellular and extracellular signaling pathways. The company was founded in 2003 and is headquartered in Buffalo, New York.
Advisors' Opinion:- [By Lisa Levin]
Cleveland BioLabs (NASDAQ: CBLI) plummeted 32.65% to $0.7610 as the company reported that BARDA has terminated negotiations related to its proposal for further development of Entolimod.
- [By Lisa Levin]
Cleveland BioLabs (NASDAQ: CBLI) shares tumbled 34.67% to touch a new 52-week low of $0.74 as the company reported that BARDA has terminated negotiations related to its proposal for further development of Entolimod.
No comments:
Post a Comment